1. Home
  2. Companies
  3. CYC
  4. Material Events

Cyclopharm (ASX:CYC) — Material Events

ASX:CYC · 20 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 14 articles Notable 4 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
14
Cyclopharm Lands 11-Site Technegas® Deal with University of Pennsylvania Health SystemMedium
Cyclopharm Secures 11-Site Technegas® Agreement with University of Pennsylvania Health System
23 Mar 2026 ·Major Contract Announcement ·85
Cyclopharm’s U.S. Surge Drives Record Revenue, Eyes 300 Installations by 2026High
Cyclopharm posts record FY2025 revenue, U.S. market leads growth; reaffirms 2026 U.S. installation guidance
2 Feb 2026 ·Trading Update ·85
Cyclopharm Raises A$16M to Fuel US Technegas Expansion Amid Record SalesHigh
Cyclopharm raises A$16M to accelerate US Technegas rollout amid record 2025 sales
4 Feb 2026 ·Capital Raising ·85
Cyclopharm Expands US Footprint with Multi-Site Northwestern Medicine DealMedium
Cyclopharm Secures Multi-Site Technegas® Agreement with Northwestern Medicine in Chicago
24 Mar 2026 ·Major Contract Announcement ·85
Cyclopharm’s Technegas Secures NIH Approval, Accelerating US GrowthMedium
Cyclopharm's Technegas Approved for Clinical Use at US NIH, Boosting US Expansion
18 Feb 2026 ·ASX Announcement ·85
Cyclopharm Accelerates US Technegas® Expansion with New Contracts and Clinical ValidationMedium
Cyclopharm accelerates US Technegas® expansion with new contracts and clinical guideline progress
31 Mar 2026 ·Commercial Update ·85
Cyclopharm Posts Record Half-Year Revenue as US Installation Target Shifts Beyond 2026Medium
Cyclopharm reports record half-year revenue, US installation guidance deferred after clinical guideline approval delay
2 July 2026 ·Operational and Financial Update ·85
Technegas Clinched as Preferred Lung Imaging Agent in New US GuidelineMedium
Technegas named preferred lung imaging agent in new US clinical guideline, boosting Cyclopharm's US market prospects
27 Jan 2026 ·ASX Announcement ·85
Cyclopharm’s US Surge Drives Record $32.3M Revenue Amid Strategic Growth PushHigh
Cyclopharm posts record AUD 32.3M revenue, US Technegas sales surge 226%, plans 250-300 US installations in 2026
25 Feb 2026 ·Appendix 4E - Preliminary Final Report ·85
Cyclopharm Accelerates US Technegas® Expansion with Four New Regional DealsMedium
Cyclopharm Expands Technegas® US Footprint with New Contracts Across Four Regions
19 Feb 2026 ·ASX Announcement ·85
Cyclopharm Doubles US Technegas Sites, Eyes 300 Installations by 2026High
Cyclopharm posts 26% revenue growth driven by USA expansion, confirms 250-300 Technegas installations target for H2 2026
27 Aug 2025 ·Appendix 4D and Half Year Report ·85
Cyclopharm’s Technegas and AI Target New COPD Treatment FrontierMedium
Cyclopharm launches COPD study using Technegas and AI to expand treatment options
29 Jan 2026 ·Clinical Study Announcement ·80
Cyclopharm’s Technegas Gains Approval in Colombia, Expanding to 67 CountriesMedium
Cyclopharm's Technegas Approved in Colombia, Now in 67 Countries
22 Dec 2025 ·Regulatory Approval Announcement ·75
Cyclopharm Clarifies NIH Contract Materiality Amid US Expansion MomentumMedium
Cyclopharm clarifies materiality of NIH Technegas® contract and confirms US expansion progress
9 Mar 2026 ·ASX Aware Letter Response ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.